Effeicacy and safety of mytoxantrone associated with flag scheme in patients with relapsed or refractory acute leukemia
Objective: The objective of this investigation was determinate the complete remission, overall survival, disease-free survival and toxicity rates in patients with relapsed or refractory acute leukemia who received FLAG plus mitoxantrone (FLAG-MITO) chemotherapy. Patients and Methods: Prospective, experimental, longitudinal, unicentric, single-arm study. Oral fludarabine 30 mg/m2BSA, cytarabine 2000 mg/m2BSA, mitoxantrone 8 mg/m2BSA and granulocyte colony-stimulating factor 300 mg every 12 hours were administrated to patients with relapsed or refractory acute leukemia.